Form 13-F position report

INNOVATE BIOPHARMACEUTICLS

Reported by NEW YORK STATE COMMON RETIREMENT FUND

NMTRQ CUSIP 45782F105 Manager CIK 0000810265

Reported 0 shares, down 20,600 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2019
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 5 Through Q2 2019

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value

Quarterly position history

How this manager's reported quarter-end position changed over time.

0 quarters
Quarterly reported position history for INNOVATE BIOPHARMACEUTICLS held by NEW YORK STATE COMMON RETIREMENT FUND.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
This position's reported history falls outside the five-year preview window. A free account unlocks it. Unlock full history

Who else reported the position

42 managers reported INNOVATE BIOPHARMACEUTICLS for Q2 2019.

Managers reporting INNOVATE BIOPHARMACEUTICLS in Q2 2019.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SABBY MANAGEMENT LLC New 1,336,248 +1,336,248 1.95% $1,550,000 1 qtr
VANGUARD GROUP INC Added 955,144 +121,104 < 0.01% $1,108,000 5 qtrs
BlackRock Inc Reduced 346,790 -862,072 < 0.01% $402,000 6 qtrs
NORTHERN TRUST CORPORATION Reduced 193,464 -26,146 < 0.01% $224,000 5 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 116,630 -60,628 < 0.01% $135,000 5 qtrs
MILLENNIUM MANAGEMENT LLC New 95,262 +95,262 < 0.01% $111,000 1 qtr
Paloma Partners Management Co New 89,694 +89,694 < 0.01% $104,000 1 qtr
MORGAN STANLEY Added 72,562 +2,714 < 0.01% $84,000 6 qtrs
GSA CAPITAL PARTNERS LLP Added 64,786 +24,186 < 0.01% $75,000 3 qtrs
Virtu Financial LLC New 62,822 +62,822 < 0.01% $73,000 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2019
Filed
August 09, 2019
Filing type
13F-HR
Position type
Common Stock

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.